Global /Japan /Healthcare /Drug Manufacturers - General /4598

Delta-Fly Pharma, Inc.

4598

• TSE: 4598 • Delayed

194JPY -2%

1.21 USD

As of 13 June 2026, Delta-Fly Pharma, Inc. has a market cap of $14.74M USD, ranking #39090 globally and #3757 in Japan. It ranks #3487 in the Healthcare sector, and #1142 in the Drug Manufacturers - General industry.

Global Rank

39090

Country Rank

3757

Sector Rank

3487

Industry Rank

1142

Key Stats

Market Cap

$14.74MUSD

2.36B JPY

Enterprise Value

$13.21MUSD

2.12B JPY

EBITDA (TTM)

-$10.28MUSD

-1.65B JPY

Net Income (TTM)

-$10.38MUSD

-1.66B JPY

PB Ratio

11.5

Company Profile

Country (HQ)

Japan

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Kiyoshi Eshima open_in_new

Employees

Founded

2010

Website

delta-flypharma.co.jp open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-2%	-3.4%	-4.3%	-18%	-57%	-61%	-60%	-83%	-86%

News

Markets

Exchange	Ticker	Price	Quotes
Tokyo Stock Exchange (TSE / TYO) MIC: XTKS PRIMARY	4598 Delta-Fly Pharma株式会社 Ordinary Shares ISIN: JP3549370009 Shares Out.: Shares Outstanding: 14.225M¹ Shares Float: 11.923M² TV: TradingView: TSE: 4598 SA: Stock Analysis: TYO: 4598 YF: Yahoo Finance: 4598.T GF: Google Finance: TYO: 4598 BA: Barron's: 4598 MS: Morningstar: XTKS: 4598	194 JPY	TV: TradingView: TSE: 4598 SA: Stock Analysis: TYO: 4598 YF: Yahoo Finance: 4598.T GF: Google Finance: TYO: 4598 BA: Barron's: 4598 MS: Morningstar: XTKS: 4598

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Delta-Fly Pharma, Inc.

Delta-Fly Pharma, Inc. develops anticancer drugs. It develops DFP-10917 that is in phase 1/2 clinical trial in the United States and phase I trial in Japan for the treatment of relapsed/refractory acute myeloid leukemia; DFP-14323, which is in phase III clinical trial to treat lung cancer; DFP-17729 that is in phase I/II clinical trials for the treatment of solid cancer; DFP-11207, which has completed phase I clinical trial to treat pancreatic cancer; DFP-14927 that is in phase I for the treatment of hematologic cancer; and DFP-10825, which is in preclinical trial to treat gastric/ovarian cancer. The company was incorporated in 2010 and is headquartered in Tokushima, Japan.

Similar Companies

Industry: Drug Manufacturers - General (Japan)

Name	Market Cap (USD) diff.	PE	Country
Chugai Pharmaceutical Co., Ltd. TSE: 4519	$81.63B 13.07T JPY 554K%	28.9	Japan
Takeda Pharmaceutical Company Ltd. TSE: 4502	$52.2B 8.36T JPY 354K%	75.1	Japan
Otsuka Holdings Co., Ltd. TSE: 4578	$36.83B 5.9T JPY 250K%	15.7	Japan
Daiichi Sankyo Company, Ltd. TSE: 4568	$30.36B 4.86T JPY 206K%	16.2	Japan
Astellas Pharma Inc. TSE: 4503	$25.81B 4.13T JPY 175K%	14.2	Japan
Shionogi & Co., Ltd. TSE: 4507	$16.9B 2.71T JPY 115K%	13.9	Japan

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 5M%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 4M%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 2M%	97.4	United States
Roche Holding AG SIX: RO	$321.52B 256.25B CHF 2M%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$288.84B 215.59B GBP 2M%	27.6	United Kingdom
Novartis AG SIX: NOVN	$274.65B 218.9B CHF 2M%	20.5	Switzerland

chevron_leftBack